JP2025500841A5 - - Google Patents
Info
- Publication number
- JP2025500841A5 JP2025500841A5 JP2024535342A JP2024535342A JP2025500841A5 JP 2025500841 A5 JP2025500841 A5 JP 2025500841A5 JP 2024535342 A JP2024535342 A JP 2024535342A JP 2024535342 A JP2024535342 A JP 2024535342A JP 2025500841 A5 JP2025500841 A5 JP 2025500841A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oea
- subject
- composition according
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265314P | 2021-12-13 | 2021-12-13 | |
| US63/265,314 | 2021-12-13 | ||
| PCT/US2022/081372 WO2023114722A1 (en) | 2021-12-13 | 2022-12-12 | Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500841A JP2025500841A (ja) | 2025-01-15 |
| JP2025500841A5 true JP2025500841A5 (enExample) | 2025-12-19 |
Family
ID=86773562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535342A Pending JP2025500841A (ja) | 2021-12-13 | 2022-12-12 | オレオイルエタノールアミドの生物学的に利用可能な製剤による肝臓脂肪変性の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250041249A1 (enExample) |
| EP (1) | EP4447950A1 (enExample) |
| JP (1) | JP2025500841A (enExample) |
| KR (1) | KR20240134319A (enExample) |
| CN (1) | CN118900687A (enExample) |
| AU (1) | AU2022416432A1 (enExample) |
| CA (1) | CA3242396A1 (enExample) |
| WO (1) | WO2023114722A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4573920A1 (en) * | 2023-12-22 | 2025-06-25 | Centre National de la Recherche Scientifique | Texturizing complex comprising oleoylethanolamide and at least one fatty substance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579413A (zh) * | 2011-01-14 | 2012-07-18 | 傅瑾 | 油酰乙醇胺及其衍生物的新用途 |
| WO2018187849A1 (en) * | 2017-04-13 | 2018-10-18 | Pharmako Biotechnologies Pty Limited | Cold-water-dispersible chemical delivery system |
| US10702487B2 (en) * | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
-
2022
- 2022-12-12 US US18/719,687 patent/US20250041249A1/en active Pending
- 2022-12-12 CN CN202280091097.4A patent/CN118900687A/zh active Pending
- 2022-12-12 JP JP2024535342A patent/JP2025500841A/ja active Pending
- 2022-12-12 EP EP22908598.0A patent/EP4447950A1/en not_active Withdrawn
- 2022-12-12 WO PCT/US2022/081372 patent/WO2023114722A1/en not_active Ceased
- 2022-12-12 KR KR1020247023563A patent/KR20240134319A/ko active Pending
- 2022-12-12 CA CA3242396A patent/CA3242396A1/en active Pending
- 2022-12-12 AU AU2022416432A patent/AU2022416432A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102088978B (zh) | 血脂异常症的改善或治疗药 | |
| US20230233472A1 (en) | Methods of preparing multiphase statin and omega-3 fatty acid soft capsule formulations | |
| JP2021107401A (ja) | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ | |
| JPWO2016117057A1 (ja) | ω３脂肪酸の自己乳化組成物 | |
| JP2019048843A5 (enExample) | ||
| TW200816934A (en) | Quercetin-containing compositions | |
| RU2001134300A (ru) | Фармацевтические и пищевые композиции, содержащие незаменимые жирные кислоты и гомоцистеин-понижающие агенты | |
| TW200816985A (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| JPWO2015008848A1 (ja) | ω３脂肪酸の自己乳化組成物 | |
| RU2761967C2 (ru) | Способ лечения, включающий пероральное или желудочное введение эдаравона | |
| US20140088047A1 (en) | Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| CN111214464A (zh) | 包含15-hepe的组合物以及其使用方法 | |
| IL303900A (en) | Medicines, treatment combinations and methods for the prevention of bacterial infections and their results | |
| CN1514725B (zh) | 包含脂肪酶抑制剂和蔗糖脂肪酸酯的药物组合物 | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| Saini et al. | Synergistic effect of piperine and its derivatives: a comprehensive review | |
| CN107847477A (zh) | 包含15‑氧代‑epa或15‑氧代‑dgla的组合物及其制备和使用方法 | |
| JP7206223B2 (ja) | パーキンソン病の予防および／または支持治療処置のための物質 | |
| JP2009539969A (ja) | メラトニン成分及びフラバノール成分を含む組成物及びキット | |
| IL228528A (en) | Potato-based nanoparticles | |
| JP2019147805A (ja) | ω３脂肪酸の自己乳化組成物 | |
| JP2009539968A (ja) | メラトニン成分及びオメガ−３−脂肪酸成分を含む組成物及びキット | |
| JP4850821B2 (ja) | リパーゼ阻害物質の使用 | |
| CN110461325A (zh) | 包括口服或胃部施用依达拉奉的治疗 |